FDA approves new drug, cemiplimab, to help prevent recurring skin cancer

A significant advancement in skin cancer treatment has arrived. The US FDA has approved cemiplimab, known as Libtayo, to help prevent certain skin cancers from returning after surgery and radiation. This new use follows strong trial results showing a substantial reduction in recurrence risk. Cemiplimab works by empowering the patient’s immune system to fight remaining cancer cells.